Dorokubicel je léčivá látka patřící do skupiny tzv. imunomodulačních látek. Používá se k léčbě některých typů rakoviny, kde pomáhá posílit vlastní obranyschopnost organismu proti nádorovým buňkám.
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD DERIVED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS). THE CD34+ HSPC FRACTION IS SELECTED FROM CORD BLOOD AND EXPANDED EX VIVO IN SERUM-FREE GROWTH MEDIUM IN THE PRESENCE OF UM171 (TRANS-N^1-[2-BENZYL-7-(2-METHYL-2H-TETRAZOL-5-YL)-9H-PYRIMIDO[4,5- B]INDOL-4-YL]CYCLOHEXANE-1,4-DIAMINE) DIHYDROBROMIDE DIHYDRATE AND RECOMBINANT CYTOKINES SUCH AS STEM CELL FACTOR (SCF), FMS-RELATED TYROSINE KINASE 3 LIGAND (FLT3L), THROMBOPOIETIN (TPO) AND INTERLEUKIN-6 (IL-6). THE EXPANDED FRACTION PREDOMINANTLY CONSISTS OF HSPCS (CD34+ CD45RACELLS), WITH VARYING LEVELS OF DENDRITIC CELL PROGENITORS (CD34+ CD86+ CELLS), MAST CELL PROGENITORS (FC EPSILON RECEPTOR IA (FCER1A)+ CD117+ CELLS), AND OTHER CELL TYPES(WHO)